科研之友
微信
新浪微博
Facebook
分享链接
摘要
PURPOSE. Mutations in the PDE6B gene cause recessive, severe retinitis pigmentosa (RP). PDE6B encodes the beta subunit of the rod-specific phosphodiesterase (beta PDE), which, when absent, results in toxic levels of intracellular Ca(2+) and photoreceptor cell death. Ca(2+) blockers, such as nilvadipine, as well as light restriction, slow photoreceptor degeneration in animal models of beta PDE deficiencies. The goal of the study was to evaluate the efficacy of AAV2/5-or AAV2/8-mediated gene replacement in combination with nilvadipine and/or with light restriction in the rd10 mouse bearing homozygous pde6b mutations. METHODS. AAV vectors encoding either beta PDE or EGFP were subretinally administered at postnatal day (P)2. Nilvadipine was administered from P7 to P28. For light restriction, pregnant rd10 mice were kept in a dark environment until their pups were 28 days old. All functional and histologic analyses were performed at P35. RESULTS. Significant morphologic photoreceptor protection was observed after subretinal administration of AAV vectors encoding EGFP. This protection further increased after administration of AAV2/8 or -2/5 encoding for beta PDE and was not associated with significant functional improvement. Photoreceptor protection was higher after AAV2/8- than after AAV2/5-mediated delivery and was not significantly augmented by additional drug therapy and/or light restriction. The protective effect was lost after P35. CONCLUSIONS. In conclusion, more efficient gene transfer tools than those used in this study, as well as a better understanding of the disease pathogenesis, should be explored to increase the effect of gene replacement and to design gene-based strategies that block the apoptotic pathways activated by beta PDE deficiency. (Invest Ophthalmol Vis Sci. 2011;52:5713-5719) DOI:10.1167/iovs.10-6269
- 出版日期2011-7
